NEW YORK -- IntraLinks® (NYSE: IL), a global technology provider of inter-enterprise content management and collaboration solutions, announced the results of the 2012 IntraLinks Global Investigator Site Survey. The survey looked at what methods are currently used for clinical trial document exchange, and the effectiveness of those methods. The survey results revealed an increased prevalence in the use of online tools from 65 percent in 2011 to 74 percent in 2012, but that there is a significant opportunity for investigator sites to improve efficiency through web-based solutions for clinical trial exchange.
The survey findings show that the majority of investigator sites are using traditional methods – email, courier and fax – as a primary tool for clinical trial document exchange. Adoption of electronic tools has grown, yet these methods continue to fall short in addressing the current document exchange needs atmost clinical trial sites:
77% of respondents (a 4% increase over the 2011 survey) use traditional methods – email (64%), courier (8%), and fax (5%) – as their primary tool for clinical trial document exchange
20% of respondents use web-based document exchange tools including Electronic Data Capture technologies (85%) and clinical portals (83%) as their main way of exchanging clinical trial documents
3% of respondents didn't select a primary method
The survey results indicate that investigator sites are experiencing significant inefficiencies and productivity challenges as a result of the ongoing use of email, courier, and fax:
58% of respondents track due dates for information, current status, or milestones manually
66% of respondents spend at least two hours, and in some cases more than nine hours, per week searching for documents
78% of respondents (up 4% from 2011) report resending documents to sponsors and Contract Research Organizations (CROs) at least once or twice, and in some cases more than five times, a week
The survey found that respondents recognize the benefits of web-based clinical document exchange tools:
71% of respondents cited being able to access updated information right away and reducing the amount of paper they use as advantages
60% of respondents cited being able to keep track of information easily as a benefit
49% of respondents cited not spending as much time searching for information as a benefit
The survey results also showed that most respondents are conducting numerous studies and those that use online clinical tools such as electronic data capture and clinical portals have a significant number of passwords and logins:
89% of respondents have conducted three to 15+ studies over the last 12 months
53% of respondents are running four to 15+ concurrent studies
83% of respondents use online clinical trial portals, up from 71 percent in 2011
"There needs to be a paradigm shift to evaluate clinical document exchange challenges from a clinical community perspective," said George Waidell, VP, life sciences practice at IntraLinks. "It is pivotal for sponsors and CROs to consider investigator sites' needs and the clinical community perspective. Deploying web-based clinical document exchange tools will enable them to reach optimal productivity gains and efficiencies."
The IntraLinks Global Investigator Site Survey was conducted online by CenterWatch, a trusted source of clinical trials information for both professionals and patients. There were 600 responses to the survey with 71% of respondents based in North America, 19% in Europe, and 5% in Asia Pacific. For more information on the survey, contact your IntraLinks representative.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Carvykti Significantly Boosts Survival, MRD Negativity in Relapsed Multiple Myeloma
December 10th 2024Phase III CARTITUDE-4 trial shows Carvykti significantly improves minimal residual disease negativity rates, progression-free survival, and overall survival compared to standard therapies for patients with relapsed or refractory multiple myeloma, especially when used earlier in treatment.